Is Truly Ra Medical Systems an Excellent Penny Stock to Buy?

The shares of commercial-stage medical gadget maker Ra Medical Systems (RMED) have tumbled 92.7% in cost over the past year as a result of capitalist worries surrounding the business’s inadequate economic health and wellness. Also, given the unpredictability surrounding the FDA’s approval of its DABRA catheter laser system, the inquiry becomes, is the penny stock a safe bet currently? Keep reading, let’s discover.

Medical device firm Ra Medical Systems, Inc. (RMED – Obtain Ranking) in Carlsbad, Calif., is styles, establishes, and also markets excimer lasers to deal with vascular illness. The company has actually made substantial progress in vital efforts, including its DABRA modern technology laser system as well as atherectomy crucial medical study. Nevertheless, the RMED stock has actually declined 86.8% in rate over the past six months as well as 92.7% over the past year, reflecting capitalist concerns over its frustrating profits and earnings growth and the sale of its dermatology company.

Closing yesterday’s session at $0.42, the stock is currently trading 95.7% listed below its 52-week high of $9.82, indicating bearish belief.

While the commercial-stage medical tool company has actually filed a 510( k) application with the united state Food and Drug Administration (FDA) for its DABRA catheter, its commercialization potential customers remain unsure up until its item receives approval from the FDA. Furthermore, the stock’s adverse earnings could make financiers distressed.

Selling Shares

Last month, RMED valued an underwritten public offering of systems of its common stock, including warrants to acquire as much as 27.6 million shares of the common stock as well as pre-funded warrants to buy as much as 14.47 shares of common stock. The medical device manufacturer anticipates roughly $12.1 million in gross earnings from the offering.

Divestiture of Dermatology Business

Top 10 Stocks for 2022
In the 3rd quarter, RMED completed the sale of its Pharos dermatology business for internet proceeds of approximately $3.5 million. This was done as a part of the business’s strategies to focus its resources on the marketplace for medical tools to treat peripheral artery illness (PAD). Nevertheless, the divestiture might negatively affect the medical device manufacturer’s profits as well as expense structure in the close to term and also trigger RMED’s stock price to tumble better.

Grim Earnings

The company’s trailing-12-month ROA as well as money from operations are negative 100.6% and $31.33 million, respectively. Furthermore, its trailing-12-month gross profit margin, ROE and also ROTC are negative 18.9%, 115%, and also 67%, respectively. And also its 0.12% property turn over proportion is 65.2% lower than the 0.34% sector standard.

Failing Financials
RMED’s internet revenue from continuing procedures can be found in at $5,000 for the 3rd quarter, finished Sept. 30, 2021, versus $68,000 in the 3rd quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss came in at $7.39 million. Moreover, its bottom line totaled up to $4.3 million, while its loss per share can be found in at $0.67. RMED reported a negative modified EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. As well as its complete operating budget grew 2.1% year-over-year to $7.15 million during this duration.

POWR Ratings Show Bleak Leads

RMED has a total D ranking, which equates to Offer in our POWR Scores system. The POWR Ratings are calculated by considering 118 distinctive aspects, with each aspect weighted to an ideal level.

Our proprietary rating system additionally assesses each stock based on eight distinct categories. RMED has an F quality for Top quality. This mirrors the stock’s adverse ROA and also capital from procedures.

The business has a D quality in Momentum, regular with its price decline over the past six months. Additionally, it has an F quality for Security, which is in sync with its fairly high beta of 1.65.

Past the qualities I have actually highlighted, one can take a look at additional RMED ratings for View, Growth, and Worth below. Amongst the 166 stocks in the D-rated Medical– Devices & Devices industry, RMED is rated # 119.


Analysts anticipate RMED’s EPS to continue to be unfavorable this year. While its initiatives to create DABRA catheters bode well, its adverse revenue margin and poor economic toughness might cause its shares to decline additionally. In addition, the unpredictability surrounding the regulative clearance and also commercialization of its DABRA laser system might elevate capitalists’ concerns. So, we assume it is finest avoided currently.

Just How Does Ra Medical Systems (RMED) Compare To its Peers?

While RMED has a total D (Market) score in our exclusive rating system, one may want to think about having a look at its industry peers, Fonar Firm (FONR – Get Score), Electromed, Inc. (ELMD – Get Ranking), and also Abbott Laboratories (ABT – Get Score), having an A (Strong Buy) score.